AstraZeneca Discontinues Five Clinical Programs, Including Three Early-Stage Cell Therapies

On July 29, AstraZeneca disclosed in its half-year financial report that it will terminateAZD5851（GPC3 CAR-T）、AZD6422（CLDN18.2 CAR-T）AndNT-125（TCR-T）The Phase I clinical development, as well as the Phase II clinical development of zibotentan + dapagliflozin for cirrhosis and Ultomiris (ravulizumab) for lupus nephritis.

Source: AstraZeneca Official Website

It is worth noting that,After the Phase I clinical trials for the three cell therapies AZD5851, AZD6422, and NT-125 were terminated, no related clinical trials are currently ongoing.

Although AstraZeneca has terminated the development of these three cell therapies, it does not mean that it is exiting the field.Reduce Layout. In the past two years, AstraZeneca has successively acquired Gracell Biotechnologies, a rising star in cell therapy, andEsoBiotec, also withCellectis Collaborates to Develop Novel Cell Therapies.

Cover Source:Corporate Logo

Disclaimer:This article is for information sharing only,不代表 Insight 立场和观点, and does not recommend or introduce any treatment options. If you have any needs, please consult and contact正规医疗机构.

Editor: Crescent

PR Article Coordination: WeChat insightxb